Insulet Co. (NASDAQ:PODD) Shares Sold by Pathstone Holdings LLC

Pathstone Holdings LLC lowered its position in Insulet Co. (NASDAQ:PODD) by 4.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,848 shares of the medical instruments supplier’s stock after selling 284 shares during the quarter. Pathstone Holdings LLC’s holdings in Insulet were worth $1,361,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in PODD. Baillie Gifford & Co. increased its holdings in Insulet by 20.7% during the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after acquiring an additional 389,639 shares in the last quarter. Clearbridge Investments LLC raised its position in shares of Insulet by 6.0% during the 2nd quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock worth $270,364,000 after purchasing an additional 75,526 shares during the last quarter. American Century Companies Inc. lifted its stake in Insulet by 18.7% in the 2nd quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock valued at $178,728,000 after buying an additional 139,246 shares in the last quarter. Marshall Wace LLP acquired a new stake in Insulet during the 2nd quarter valued at $99,978,000. Finally, Federated Hermes Inc. increased its position in Insulet by 38.8% during the second quarter. Federated Hermes Inc. now owns 369,113 shares of the medical instruments supplier’s stock worth $74,487,000 after buying an additional 103,266 shares in the last quarter.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PODD. UBS Group upped their price objective on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Morgan Stanley raised their price target on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Sanford C. Bernstein initiated coverage on shares of Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective for the company. BTIG Research raised their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Finally, Piper Sandler boosted their price target on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Stock Up 0.2 %

PODD opened at $266.92 on Friday. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $279.40. The firm has a 50 day moving average price of $243.21 and a 200 day moving average price of $212.74. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company has a market cap of $18.72 billion, a PE ratio of 45.71, a price-to-earnings-growth ratio of 4.08 and a beta of 1.22.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.